Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






Cancer News Breast Duct Treatment For Early Breast Cancer Eliminates All Signs Of Disease In Laboratory Experiments Next Step Is To Study In Women Receiving Mastectomy Science Daily

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Cancer News Breast Duct Treatment For Early Breast Cancer Eliminates All Signs Of Disease In Laboratory Experiments Next Step Is To Study In Women Receiving Mastectomy Science Daily is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


Cancer News Breast Duct Treatment For Early Breast Cancer Eliminates All Signs Of Disease In Laboratory Experiments Next Step Is To Study In Women Receiving Mastectomy Science Daily | RobinsPost News & Noticias

Adjuvant giredestrant improves invasive DFS in early breast cancer subset


Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage, ER-positive, HER2-negative breast cancer.The findings were presented at ... Read More

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer


The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ... Read More

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence


In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ... Read More

Giredestrant Improves Outcomes in ER+/HER2– Breast Cancer


Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or death by 30% in ER-positive, HER2-negative early breast cancer. Read More

Turning Data Into Confidence: A New Era of Precision in Breast Cancer Care


The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers. “DCISionRT is becoming the standard of care for physicians and patients ... Read More

Cryoablation: The Minimally Invasive Freezing Technology That’s a Game-Changer for Treating Low-Risk, Early-Stage Breast Cancer


Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer tumors to kill them — is emerging as a new option. Read More

7 early signs of breast cancer and why knowledge is power in this disease


Breast cancer isn’t just a woman’s issue, though it is more common in women; it can affect men, too. And often, this disease begins silently, with signs so subtle that they get ignored or brushed ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus